31.01.20: Not intended for U.S. and UK Media
Bayer receives positive CHMP opinion for darolutamide as a new treatment for men with non-metastatic castration-resistant prostate cancerCHMP opinion is based on Phase III ARAMIS trial data evaluating the efficacy and safety of darolutamide plus androgen deprivation therapy (ADT) compared to placebo plus ADT / Final decision from the European Commission is anticipated within the coming monthsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - January 30, 2020 Category: Pharmaceuticals Source Type: news
30.01.20: Not intended for U.S. and UK Media - Updated results of Phase III trial show:
Darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancerFull data to be presented at upcoming scientific meetingmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - January 30, 2020 Category: Pharmaceuticals Source Type: news
23.01.20: Not intended for U.S. and UK Media
Bayer submits application to European Medicines Agency for pre-filled syringe to administer eye medication Eylea®mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - January 23, 2020 Category: Pharmaceuticals Source Type: news
23.01.20: Not intended for U.S. and UK Media
Bayer receives approval for darolutamide in JapanMarketing authorization granted for the treatment of men with non-metastatic castration-resistant prostate cancermehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - January 22, 2020 Category: Pharmaceuticals Source Type: news
21.01.20: Kepler Cheuvreux German Corporate Conference, Frankfurt, Germany
Kepler Cheuvreux German Corporate Conference, Frankfurt, GermanyLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - January 20, 2020 Category: Pharmaceuticals Source Type: news
20.01.20: Kepler Cheuvreux German Corporate Conference, Frankfurt, Germany
Kepler Cheuvreux German Corporate Conference, Frankfurt, GermanyLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - January 19, 2020 Category: Pharmaceuticals Source Type: news
14.01.20: J.P. Morgan Healthcare Conference, San Francisco, California
J.P. Morgan Healthcare Conference, San Francisco, CaliforniaLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - January 13, 2020 Category: Pharmaceuticals Source Type: news
13.01.20: Not intended for U.S. and UK Media
Bayer and Daré Bioscience enter into exclusive license agreement for U.S. commercial rights to investigational hormone-free, monthly contraceptive Ovaprene®Underlining Bayer's commitment in the field of women's health / Potential commercial milestone payments of up to USD 310 million and tiered royalties on net sales in the double-digit rangemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - January 13, 2020 Category: Pharmaceuticals Source Type: news
13.02.20: Crop Science R&D Pipeline Update
Crop Science R&D Pipeline UpdateLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - January 9, 2020 Category: Pharmaceuticals Source Type: news
25.06.20: Capital Markets Day, Berlin, Germany
Capital Markets Day, Berlin, GermanyLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - December 18, 2019 Category: Pharmaceuticals Source Type: news
26.06.20: Capital Markets Day, Berlin, Germany
Capital Markets Day, Berlin, GermanyLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - December 18, 2019 Category: Pharmaceuticals Source Type: news
10.12.19: Bayer to significantly step-up its sustainability efforts
Bayer to significantly step-up its sustainability efforts2030 target to be carbon neutral in own operations / Ambitious 2030 objectives for access to health and nutrition in low- and middle-income countries and underserved communities / Measurable sustainability targets to be incorporated into management compensationmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - December 10, 2019 Category: Pharmaceuticals Source Type: news
29.11.19: Bayer completes sale of Currenta stake to Macquarie Infrastructure and Real Assets
Bayer completes sale of Currenta stake to Macquarie Infrastructure and Real AssetsFurther step in Bayer's efforts to sharpen focus on core businessmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 29, 2019 Category: Pharmaceuticals Source Type: news
04.12.19: Berenberg European Conference, Pennyhill, UK
Berenberg European Conference, Pennyhill, UKLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 27, 2019 Category: Pharmaceuticals Source Type: news
05.12.19: Societe Generale The Premium Review Conference, Paris, France
Societe Generale The Premium Review Conference, Paris, FranceLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 27, 2019 Category: Pharmaceuticals Source Type: news
